876 related articles for article (PubMed ID: 34838785)
1. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
[TBL] [Abstract][Full Text] [Related]
3. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
Ahmed S; Kanakry JA; Ahn KW; Litovich C; Abdel-Azim H; Aljurf M; Bacher VU; Bejanyan N; Cohen JB; Farooq U; Fuchs EJ; Bolaños-Meade J; Ghosh N; Herrera AF; Hossain NM; Inwards D; Kanate AS; Martino R; Munshi PN; Murthy H; Mussetti A; Nieto Y; Perales MA; Romee R; Savani BN; Seo S; Wirk B; Yared JA; Sureda A; Fenske TS; Hamadani M
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1859-1868. PubMed ID: 31132455
[TBL] [Abstract][Full Text] [Related]
4. Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC.
Bailén R; Pascual-Cascón MJ; Guerreiro M; López-Corral L; Chinea A; Bermúdez A; Sampol A; Heras I; García-Torres E; Torres M; Roca JR; Herruzo B; Sanz J; Fonseca M; Herrera P; Colorado M; Bento L; López-Godino O; Martín-Calvo C; Fernández-Caldas P; Marcos-Jubilar M; Sánchez-Ortega I; Solano C; Noriega V; Humala K; Oarbeascoa G; Díez-Martín JL; Kwon M;
Transplant Cell Ther; 2022 Apr; 28(4):204.e1-204.e10. PubMed ID: 35108627
[TBL] [Abstract][Full Text] [Related]
5. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.
Nakaya Y; Koh H; Konuma T; Shimomura Y; Ishiyama K; Itonaga H; Hino M; Doki N; Nishida T; Ohigashi H; Matsuoka KI; Kanda Y; Maruyama Y; Sawa M; Eto T; Hiramoto N; Fukuda T; Atsuta Y; Nakamae H
Transplant Cell Ther; 2024 Mar; 30(3):316.e1-316.e12. PubMed ID: 38108263
[TBL] [Abstract][Full Text] [Related]
6. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Montoro J; Boumendil A; Finel H; Bramanti S; Castagna L; Blaise D; Dominietto A; Kulagin A; Yakoub-Agha I; Tbakhi A; Solano C; Giebel S; Gulbas Z; López Corral L; Pérez-Simón JA; Díez Martín JL; Sanz J; Farina L; Koc Y; Socié G; Arat M; Jurado M; Bermudez A; Labussière-Wallet H; Villalba M; Ciceri F; Martinez C; Nagler A; Sureda A; Glass B
Transplant Cell Ther; 2024 Feb; 30(2):210.e1-210.e14. PubMed ID: 38043802
[TBL] [Abstract][Full Text] [Related]
7. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
8. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.
Barkhordar M; Kasaeian A; Janbabai G; Mousavi SA; Fumani HK; Tavakoli S; Bahri T; Ghavamzadeh A; Vaezi M
Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087
[TBL] [Abstract][Full Text] [Related]
10. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
[TBL] [Abstract][Full Text] [Related]
11. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
12. Peritransplantation Glucocorticoid Haploidentical Stem Cell Transplantation Is a Promising Strategy for AML Patients With High Leukemic Burden: Comparison With Transplantations Using Other Donor Types.
Kaida K; Ikegame K; Inoue T; Maruyama S; Ishii S; Uchida N; Doki N; Eto T; Fukuda T; Katayama Y; Takada S; Kawakita T; Ichinohe T; Atsuta Y; Daimon T; Ogawa H
Transplant Cell Ther; 2023 Apr; 29(4):273.e1-273.e9. PubMed ID: 36641032
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis.
Ma L; Han X; Jiang S; Meng Q; Zhang L; Bao H
Hematology; 2020 Dec; 25(1):356-365. PubMed ID: 33054609
[TBL] [Abstract][Full Text] [Related]
14. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
15. Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts.
Arcuri LJ; Hamerschlak N; Rocha V; Bonfim C; Kerbauy MN
Transplant Cell Ther; 2021 Sep; 27(9):782.e1-782.e7. PubMed ID: 34146733
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM
Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648
[TBL] [Abstract][Full Text] [Related]
17. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide.
DeZern AE; Elmariah H; Zahurak M; Rosner GL; Gladstone DE; Ali SA; Huff CA; Swinnen LJ; Imus P; Borrello I; Wagner-Johnston ND; Ambinder RF; Brodsky RA; Cooke K; Luznik L; Fuchs EJ; Bolaños-Meade J; Jones RJ
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2075-2081. PubMed ID: 32818556
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.
Brissot E; Labopin M; Moiseev I; Cornelissen JJ; Meijer E; Van Gorkom G; Rovira M; Ciceri F; Griskevicius L; Blaise D; Forcade E; Mistrik M; Mielke S; Bulabois CE; Niittyvuopio R; Deconinck E; Ruggeri A; Sanz J; Spyridonidis A; Savani B; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2020 Jul; 13(1):87. PubMed ID: 32620146
[TBL] [Abstract][Full Text] [Related]
19. Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.
Solh MM; Baron J; Zhang X; Bashey A; Morris LE; Holland HK; Solomon SR
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2082-2088. PubMed ID: 32745575
[TBL] [Abstract][Full Text] [Related]
20. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
